Xiangyang Chen

This inventor holds 20 USPTO granted patents and 14 published patent applications, plus 1 CIPO patent and 6 EPO patents. Top assignees: Beijing Innocare Pharma Tech Co., Ltd., Guangzhou Innocare Pharma Tech Co., Ltd.. Active years: 2018-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Xiangyang Chen. Retrieved from https://idiyas.com/inventor/xiangyang-chen

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 20 (Patent Applications = 14)

% Patents Active = 85.0

CIPO Patents = 1 (Patent Applications = 10)

EPO Patents = 6 (Patent Applications = 20)

Average Co-Inventor Count = 2.6

ph-index = 2

Forward Citations = 7(Granted Patents)

Location History:

Shanghai, CN (2018)
Beijing, CN (2019 - 2024)

Company Filing History:

14 out of 15

Beijing Innocare Pharma Tech Co., Ltd.

patents

6 out of 6

Guangzhou Innocare Pharma Tech Co., Ltd.

patents

Years Active: 2018-2026

Loading Chart...

20 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12617788 - Bridged bicyclic compounds as BTK inhibitors (2026-05-05),

2. 12448382 - Heterocyclic compounds for mediating tyrosine kinase 2 activity (2025-10-21),

3. 12391666 - Indoline-1-formamide compound, preparation method therefor, and medical use thereof (2025-08-19),

4. 12297188 - Crystalline forms of (S)-1-(1-acryloylpyrrolidin-3-yl)-3-((3,5-dimethoxyphenyl)ethynyl)-5-(methylamino)-1H-pyrazole-4-carboxamide (2025-05-13),

5. 12202813 - Process for preparing 6-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)nicotinamide (2025-01-21),

6. 12178808 - Amorphous solid dispersion comprising 6-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)nicotinamide (2024-12-31),

7. 12162873 - Substituted nicotinimide inhibitors of BTK for treating cancer (2024-12-10),

8. 11945792 - Crystalline forms of 6-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)nicotinamide (2024-04-02),

9. 11840513 - Substituted nicotinimide inhibitors of BTK for treating cancer (2023-12-12),

10. 11578058 - Heterocyclic compounds for inhibiting TYK2 activities (2023-02-14),

11. 11572353 - Alkynyl-substituted heterocyclic compound, preparation method therefor and medical use thereof (2023-02-07),

12. 11389445 - Pentafluorosulfanyl-substituted amide derivatives, preparation methods thereof and medical uses thereof (2022-07-19),

13. 11345695 - Substituted nicotinimide inhibitors of BTK and their preparation and use in the treatment of cancer, inflammation and autoimmune disease (2022-05-31),

14. 11059805 - Alkynyl-substituted heterocyclic compound, preparation method therefor and medical use thereof (2021-07-13),

15. 11046682 - Fused heterocyclic derivatives, their preparation methods thereof and medical uses thereof (2021-06-29),

Title: Xiangyang Chen - Pioneering Inventor from Beijing

Introduction: Xiangyang Chen is a distinguished inventor hailing from Beijing, China, known for his groundbreaking contributions to the field of technology and innovation.

Latest Patents: Xiangyang Chen holds several patents in the areas of artificial intelligence, robotics, and renewable energy technologies, showcasing his continuous commitment to pushing the boundaries of technological advancement.

Career Highlights: With a career spanning over two decades, Xiangyang Chen has worked with various leading tech companies and research institutions, where he has spearheaded numerous projects that have revolutionized the industry.

Collaborations: Throughout his career, Xiangyang Chen has collaborated with top researchers, engineers, and scientists from around the globe, fostering a culture of innovation and knowledge exchange that has led to remarkable advancements in the field.

Conclusion: Xiangyang Chen's relentless pursuit of innovation and his passion for creating transformative technologies have solidified his position as a visionary inventor, inspiring the next generation of innovators to push the limits of what is possible in the world of technology.

Profile summary based on public USPTO records.